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Context: Previous studies have shown that the endocannabinoid system plays a major role in en-
ergy metabolism through the actions of its main mediators, 2-arachidonoyl-sn-glycerol (2-AG) and
anandamide (AEA).
Objective:We examined serum levels of major endocannabinoid mediators and their association with
clinical parameters in patients with end-stage renal disease (ESRD).
Design and Setting: Serum concentrations of 2-AG and AEA were measured in patients on main-
tenance hemodialysis (MHD) and controls, and correlations with various clinical and laboratory indices
were examined. 2-AG was also measured in age and sex-matched healthy subjects for comparison of
levels in patients undergoing MHD.
Main Outcome Measure: Serum 2-AG.
Results: Serum 2-AG levels were significantly elevated in patients with ESRD compared with healthy
controls. Higher levels of 2-AG were found in patients on MHD compared to healthy subjects, and
similar findings were seen in a second set of subjects in independent analyses. Among 96 patients on
MHD, 2-AG levels correlated significantly and positively with serum triglycerides (r 5 0.43; P ,
0.0001), bodymass index (r5 0.40;P, 0.0001), and body anthropometricmeasures and negatively with
serumhigh-density lipoprotein cholesterol (r520.33;P5 0.001) following adjustment for demographic
and clinical variables.
Conclusions: In patients on MHD, levels of serum 2-AG, a major endocannabinoid mediator, were
increased. In addition, increasing serum 2-AG levels correlated with increased serum triglycerides and
markers of body mass. Future studies will need to evaluate the potential mechanisms responsible for
these findings.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
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The prevalence of chronic kidney disease (CKD) in the United States and worldwide has
increased dramatically over the past few decades [1, 2]. It is well known that patients with
advanced CKD and end-stage renal disease (ESRD) have a significantly increased risk of all-
cause and cardiovascular mortality, and in spite of many recent improvements, patients with
ESRD on maintenance hemodialysis (MHD) continue to experience an annual mortality rate
of approximately 17% per year [3]. The factors responsible for this disproportionately ele-
vated risk of death have not been fully identified. In fact, traditional risk factors such as
obesity and hypertriglyceridemia cannot explain the magnitude of the risk observed in these
patients, given that they are paradoxically associated with better survival in observational
studies [4, 5]. Conversely, there is accumulating evidence that cachexia (protein energy
wasting) and impaired energy metabolismmay play a more prominent role in the higher risk
of mortality in patients with ESRD [6, 7].
Although recent research has shown that the endocannabinoid systemmay counteract the
effects of cachexia [8], its role in patients with ESRD has not yet been examined. This system
is composed of endogenous, bioactive, lipid-derived mediators, the endocannabinoids, which
exert their effects through specific G protein‒coupled receptors: cannabinoid (CB)-1 and CB2.
The most extensively studied endocannabinoids are anandamide (AEA) and 2-arachidonoyl-
sn-glycerol (2-AG) [8, 9]. The endocannabinoid system plays important roles inmany different
physiologic processes, especially energy metabolism, by overseeing energy requirements and
expenditure. Activation of the endocannabinoid system leads to increased intake of energy-
rich foods and decreased energy expenditure via promotion of white adipogenesis and in-
hibition of brown adipose tissue activation [8, 10–12]. In addition, endocannabinoid system
activation stimulates molecular pathways involved in energy storage, including fatty acid
synthesis and lipogenesis. Therefore, it is not surprising that overactivity of this system has
been associated with obesity, hypertriglyceridemia, and metabolic syndrome in animals and
humans [8, 11, 12]. In addition, recent studies in patients with obesity have found elevated
serum levels of endocannabinoids, and extensive work has demonstrated a causative re-
lationship between abnormal endocannabinoid system activity and development of metabolic
syndrome [13–15].
Given that ESRD treated with MHD is associated with abnormal energy metabolism and
cachexia, we hypothesized that serum AEA and/or 2-AG levels may be altered in this patient
population. We sought to evaluate how alterations in serum AEA and/or 2-AG levels in MHD
patients correlate with laboratory and clinical parameters. We measured and compared
concentrations of serum AEA and 2-AG inMHD patients and healthy controls and tested our
findings from the MHD cohort in a second set of independent analyses in another laboratory
using liquid chromatography/mass spectrometry techniques.
1. Materials and Methods
A. Study Population
The study population consisted of healthy controls and MHD patients. Healthy subjects
(without hypertension, diabetes, other major cardiovascular comorbidities, or medication
use) were recruited for this study by the University of California (UC), Irvine Institute for
Clinical and Translational Science. MHD patients were randomly selected from a subcohort
of MHD patients who were enrolled in the initial phase of the Malnutrition, Diet, and Racial
Disparities in Chronic Kidney Disease (MADRAD) study (ClinicalTrials.gov NCT01415570)
and had an available laboratory measurement collected between April and July 2014. MHD
patients were matched to healthy controls according to age (610 years) and sex. MADRAD
is a prospective cohort study examining differences in dietary factors and nutritional status
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across racial/ethnic groups of MHD patients recruited from outpatient dialysis facilities in
the South Bay‒Los Angeles, California area. The enrollment criteria of MADRAD have been
previously described [16].
Serum levels of 2-AG and AEA were measured in 50 MHD patients and 21 age- and sex-
matched healthy controls. Additional MHD patients were added for comparisons of serum
2-AG in 96 total MHD patients and 21 healthy controls (Supplemental Fig. 1 in an online
repository [17]). Then, to test the robustness of our findings, we repeated these analyses
with a second set of subjects in another laboratory with expertise in extraction and analysis of
endocannabinoids. The second set of subjects included 10 healthy controls and 37 age-, sex-,
race-, and ethnicity-matched MHD patients with serum AEA and 2-AG measurements. The
2-AG and AEA levels were measured in serum samples obtained from all patients before
hemodialysis treatments at baseline. Serum was collected during the same time as rou-
tine blood tests conducted at dialysis clinics and was frozen at 280°C until analyses
were performed.
The study was approved by the institutional review committees of the Los Angeles Bio-
medical Research Institute at Harbor-UCLA, Torrance, California, and the UC Irvine
Medical Center, Orange, California. Patients were included in the study if they provided
written/signed informed consent.
B. Lipid Extraction and Analysis
In the first set of analyses, methanol (1.5 mL) containing internal standards [2H4]AEA
(1 pmol) and [2H8]2AG (250 pmol) was added to serum (0.75 mL). Lipids were extracted
using chloroform (3 mL) and 0.1 M sodium chloride (1 mL). The organic phases were dried
under N2, reconstituted in chloroform (2 mL), and applied to open-bed silica gel columns to
fractionate lipid groups on the basis of polarity. Eluted fractions containing AEA and
arachidonoylglycerol (chloroform/methanol, 9:1, v/v) were dried under N2, and the residue
was reconstituted in a 60-mL solvent mixture of chloroform and methanol (1:3, v/v) for liquid
chromatography/mass spectrometry and liquid chromatography with tandem mass spec-
trometry analyses (for additional details on lipid extraction and analysis, see the supple-
mental material [17]).
The verification analyses were performed in a separate independent laboratory (Dr.
Nicholas DiPatrizio) with expertise in endocannabinoid extraction and analysis in human
samples [18–20].Methanol (1mL) containing internal standards [2H4]AEA (1 pmol) and [
2H5]
2AG (250 pmol) was added to serum (0.5 mL). Lipids were extracted using chloroform (2 mL)
and 0.1 M sodium chloride (0.5 mL). The organic phases were dried under N2, reconstituted
in chloroform (2 mL), and applied to open-bed silica gel columns to fractionate lipid groups
on the basis of polarity. Eluted fractions containing AEA and 2-AG (chloroform/methanol,
9:1, v/v) were dried under N2, and the residue was reconstituted in a 100-mL solvent mixture
of chloroform and methanol (1:1, v/v) for ultra performance liquid chromatography with
tandem mass spectrometry analyses (for additional details on lipid extraction and analysis,
see the supplemental material [17]).
C. Demographic, Clinical, and Laboratory Characteristics of MHD Patients
Baseline demographic and clinical data (including age, sex, race, and ethnicity) were ob-
tained by MADRAD study coordinators. Diabetes as a preexisting comorbid condition was
ascertained by MADRAD study coordinators according to patient self-reported history and
obtained via International Classification of Diseases, Ninth Revision codes at the time of
study entry. Dialysis vintage for MHD patients was calculated as the interval of time
between the date of the patient’s first dialysis treatment and the date of serum AG or
AEA measurement. Data on body mass index (BMI) using postdialysis weight were also
obtained from electronic records of the dialysis facilities. In addition, patient body com-
position surrogates were measured by MADRAD study coordinators during treatment
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visits. Further details about the MADRAD study ascertainment of body anthropometry have
been previously reported [16].
Routine laboratory measurements including lipid panels were obtained from electronic
records of the dialysis facilities. Blood samples were drawn using standardized techniques
and measured using automated and standardized methods at a central laboratory in Deland,
Florida, typically within 24 hours. An extended serum lipid panel was measured at the UC
Irvine Medical Center laboratory. Very-low-density lipoprotein concentrations were mea-
sured and not calculated. Serum concentrations of IL-6 were determined using ELISA
(Waltham, MA) assay kits from R&D Systems (Minneapolis, MN) and Affymetrix Thermo
Fisher Scientific (Waltham, MA) per manufacturer’s protocol.
D. Beck Depression Index Score and Quality of Life Measures
To assess depression and the severity of its symptoms over the past 2 weeks prior to as-
sessment, patients completed the Beck Depression Inventory-II questionnaire. The Beck
Depression Inventory-II score is the sum of the responses to 21 questions, each ranked on a
scale from 0 to 3. Patients also completed the 36-Item Short Form Health Survey quality of
life questionnaire. The responses to individual questions were scored and then calculated to
assess patient physical and mental health domains, as well as eight dimensions of health:
physical functioning, role limitations due to physical health, role limitations due to personal
or emotional problems, energy/fatigue, emotional well-being, social functioning, bodily pain,
and general health [21].
In all analyses, laboratory tests and health questionnaire scores collected closest to the
date of serum 2-AG or AEA measurement were used.
E. Statistical Analyses
The distribution of serum 2-AGwas presented as a histogram (Supplemental Fig. 2 [17]), and
the normality of serum 2-AG andAEAwas evaluatedwith Shapiro-Wilk tests. In all analyses,
serum 2-AG and AEA levels were described using medians [interquartile range (IQR)].
Baseline patient characteristics were summarized with means 6 SDs, medians (IQR), or
proportions where appropriate. Comparisons of serum 2-AG and AEA levels between MHD
patients and healthy controls were conducted using the nonparametric Wilcoxon‒Mann-
WhitneyU test. Furthermore, serum 2-AG and AEA levels were compared between strata of
demographic and clinical characteristics in MHD patients using similar methods.
Spearman rank correlation coefficients (r) were calculated to describe the relationship
between serum 2-AG and AEA levels with clinical and laboratory markers and additionally
with body anthropometric measures, quality of life, and depression scores. Correlation an-
alyses were adjusted for age, sex, race, ethnicity, diabetes, and dialysis vintage covariates.
Data on BMI were sourced primarily from large dialysis organization electronic records
or imputed with available BMI levels collected by MADRAD study coordinators for
those missing BMI (14%). All patients had complete data on all covariates. Two-sided
P values,0.05 were considered statistically significant. For correlation analyses in the
primary cohort, we used a stricter definition of P value ,0.0001 to be considered significant
to account for multiple comparisons. Analyses were performed using SAS, version 9.4 (SAS
Institute Inc., Cary, NC).
2. Results
A. Cohort Characteristics
The primary cohort consisted of 96 MHD patients. Baseline characteristics are presented in
Table 1. The mean (6SD) age of the cohort was 52 6 12 years; 64% were female, and 52%
had diabetes.
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In examination of serum endocannabinoid levels, we found that median (IQR) concen-
trations of serum 2-AG were higher in 96 MHD patients [76 (49 to 163) pmol/mL] than in 21
controls [25 (11 to 37) pmol/mL] (Fig. 1A). Similar results for serum 2-AG were found in the
confirmatory analysis of 10 controls and 37 age-, sex-, race-, and ethnicity-matched MHD
patients. Levels of serum 2-AG were significantly higher in MHD patients than in controls
[median (IQR), 45 (26 to 68) pmol/mL and 10 (9 to 13) pmol/mL, respectively] (Fig. 1B). In
contrast, serum AEA concentrations were lower in 50 MHD patients than in 21 controls:
median (IQR), 1.00 (0.82 to 1.29) pmol/mL and 1.88 (1.31 to 2.35) pmol/mL, respectively (Fig.
2A). These findings were similarly observed in a second independent laboratory using a
separate set of 10 controls and 37 age-, sex-, race-, and ethnicity-matched unique MHD
patients with the following AEA measurements: median (IQR), 1.91 (1.61 to 2.38) pmol/mL
and 1.01 (0.71 to 1.21) pmol/mL, respectively (Fig. 2B). We also examined serum 2-AG and
AEA levels according to demographic and clinical characteristics among MHD patients but
found no differences in 2-AG or AEA concentrations within each group (Table 2).
B. Correlations of Serum 2-AG and AEA With Clinical and Laboratory Indices
Serum 2-AG positively correlated with BMI, midarm circumference, biceps and triceps skin
folds, serum triglyceride (TG) levels, and very-low-density lipoprotein cholesterol (VLDL-C)
after adjustment for age, sex, race, ethnicity, diabetes, and dialysis vintage covariates
Table 1. Baseline Characteristics of 96 Patients Undergoing Maintenance Hemodialysis
Variable Total
N 96
Age 6 SD, y 52 6 12
Female, % 64
Race, %
White 83
Asian 17
Hispanic ethnicity, % 53
Diabetes, % 52
Access type, %
AV fistula 69
AV graft 6
Central venous catheter 25
Body mass index, kg/m2 27.9 6 6.3
Laboratory tests
Albumin, g/dL 4.0 6 0.3
Creatinine, mg/dL 9.3 6 3.1
Ferritin, ng/mL 619 (387–886)
TIBC, mg/dL 231.2 6 38.2
PTH, pg/mL 380 (265–576)
Lipid panel
VLDL-C, mg/dL 12 (6–28)
Triglycerides, mg/dL 126 (92–213)
Cholesterol, mg/dL 143.1 6 38.8
HDL-C, mg/dL 42.2 6 20.2
LDL-C, mg/dL 77.3 6 28.4
LPA-C, mg/dL 2 (1–4)
NHDL, mg/dL 100.8 6 39.2
IL-6, pg/mL 2 (1–5)
Vintage, d 1363 (683–2270)
Data are presented as percentages, mean 6 SD, or median (interquartile range) where appropriate.
Abbreviations: AV, arteriovenous; HDL-C, high-density lipoprotein cholesterol; IL-6, interleukin-6; LDL-C, low-
density lipoprotein cholesterol; LPA-C, lipoprotein(a) cholesterol; NHDL, non‒high-density lipoprotein; PTH,
parathyroid hormone; TIBC, total iron-binding capacity; VLDL-C, very-low-density lipoprotein cholesterol.
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(Table 3). Conversely, serum 2-AG negatively correlated with serum high-density lipoprotein
cholesterol (HDL-C; r 5 20.33; P 5 0.001). After consideration for multiple comparisons,
Spearman correlation coefficients only for VLDL-C, TG, and BMI with 2-AG remained
statistically significant. Unadjusted and adjusted correlation coefficients of 2-AG with ad-
ditional laboratory tests, quality of life, and depression data are presented in Supplemental
Table 1 [17].
There were no significant correlations between serum AEA and seven lipid panels (VLDL-
C, TG, cholesterol, HDL-C, low-density lipoprotein cholesterol, lipoprotein(a)-cholesterol,
and non‒high-density lipoprotein; Supplemental Table 2 [17]). The correlations between
serum AEA and normalized protein catabolic rate and unsaturated iron-binding capacity
were modest but significant (r 5 20.43; P 5 0.004 and r 5 0.32; P 5 0.03, respectively)
following adjustment for age, sex, race, ethnicity, diabetes, and dialysis vintage covariates.
Figure 2. First and confirmatory analyses of serum AEA concentrations in patients
receiving MHD compared with control subjects. (A) Serum AEA concentrations in the first
analysis of 50 MHD patients and 21 control subjects. (B) Serum AEA concentrations in the
confirmatory analysis of 37 MHD patients and 10 control subjects. P , 0.0001 for both,
Wilcoxon‒Mann-Whitney U test. Horizontal lines in boxplots represent the median, circle
and cross in boxplots represent the mean in the control and MHD groups, respectively, error
bars represent the lower (25th percentile - 1.5*IQR) and upper (75th percentile 1 1.5*IQR)
boundaries, and crosses outside boxplots represent outliers.
Figure 1. First and confirmatory analyses of serum 2-AG concentrations in patients
receiving MHD compared with control subjects. (A) Serum 2-AG concentrations in the first
analysis of 96 MHD patients and 21 control subjects. (B) Serum 2-AG concentrations in the
confirmatory analysis of 37 MHD patients and 10 control subjects. Serum 2-AG levels are
presented on a logarithmic scale for visual purposes only. P , 0.0001 for both, Wilcoxon‒
Mann-Whitney U test. Horizontal lines in boxplots represent the median, circle and cross in
boxplots represent the mean in the control and MHD groups, respectively, error bars
represent the lower (25th percentile - 1.5*IQR) and upper (75th percentile 1 1.5*IQR)
boundaries, and crosses outside boxplots represent outliers.
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3. Discussion
ESRD is associated with a disproportionately elevated risk of death. Traditional risk factors
for mortality such as obesity and hypertriglyceridemia do not consistently explain the
mortality risk observed in these patients and can be associatedwith improved outcomes [4, 5].
Alternatively, cachexia is a common complication of ESRD and plays a prominent role in the
morbidity and mortality associated with this disease [6]. Therefore, there has been a focus on
identifying cachexia-related risk factors, which can better explain ESRD-associated mor-
tality and provide new potential targets for therapy [22].
In this regard, data on the association of endocannabinoids with clinical and laboratory
markers are very limited in patients with ESRD. The only available report is a study by
Friedman et al. [23], which did not find any differences in plasma (EDTA-preserved tubing)
endocannabinoid levels between healthy controls and patients with ESRD. However, it
should be noted that the small sample size (n 5 20), significant sex differences between the
control and ESRD groups, and use of plasma (vs our samples which were serum) in their
study make interpretation and comparison with our study difficult [23]. Our study eval-
uated serum endocannabinoid levels in a large cohort of patients with ESRD who were
compared with age- and sex-matched healthy controls. We found significantly increased
serum concentrations of 2-AG in patients with ESRD undergoing MHD, as measured in two
different laboratories and two separate sets of patients and controls. In MHD patients,
serum concentrations of 2-AG positively correlated with serum TG and TG-rich lipoprotein
levels. In addition, serum 2-AG levels correlated positively with BMI and indices of in-
creased body fat and midarm circumference on anthropometric measurements. These
findings are in line with available literature indicating that higher serum endocannabinoid
levels can be associated with increased body fat content [11]. Furthermore, serum 2-AG
levels negatively correlated with serum HDL-C concentrations, which is consistent with
previously published data regarding the role of the endocannabinoid system in HDL
metabolism [24–26].
Table 2. Serum AEA and 2-AG Levels in Patients Undergoing MHD Stratified by Demographic and
Clinical Characteristics
Subgroup
Endocannabinoids
Serum AEA (pmol/mL) n 5 50 Serum 2-AG (pmol/mL) n 5 96
Median (IQR) P Value Median (IQR) P Value
Age, y
,50 0.98 (0.82–1.16) 0.37 73 (51–161) 0.73
$50 1.05 (0.82–1.29) 78 (48–165)
Sex
Female 0.96 (0.76–1.29) 0.19 81 (53–177) 0.25
Male 1.05 (0.95–1.43) 75 (44–127)
Race
White 1.00 (0.89–1.33) 0.38 80 (48–172) 0.19
Asian 0.88 (0.76–1.29) 67 (51–101)
Ethnicity
Hispanic 0.98 (0.89–1.26) 0.78 83 (52–216) 0.13
Non-Hispanic 1.05 (0.76–1.35) 73 (48–127)
Dialysis vintage, d
,1095 0.99 (0.82–1.29) 0.62 96 (51–172) 0.42
$1095 1.02 (0.83–1.33) 72 (48–144)
Presence of diabetes
Yes 0.98 (0.88–1.53) 0.43 78 (48–174) 0.63
No 1.01 (0.77–1.17) 75 (49–142)
Data are presented as median (IQR).
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It is also interesting to note that although activation of the endocannabinoid system may
be partly responsible for the associations observed in this study, it may not be the only
mechanism at play, given that our findings are unique to 2-AG and that serumAEA levels did
not have similar correlations with clinical and laboratorymarkers. In this regard, differential
changes and correlations observed for 2-AG and AEA in our study were also observed in other
studies [27, 28]. The mechanisms responsible for and implications of these findings are less
clear. However, in a study by Coˆte´ et al. [29], it was argued that 2-AG, rather than AEA, was
the more selective and effective activator of the EC system, pointing out that AEA has also
been reported to bind to several other targets. Therefore, it was argued that differential
changes in these two endocannabinoid mediators during physiologic or pathologic conditions
can be observed, given that they may be mediating different effects [29]. However, it is also
important to recognize that clear mechanisms that can account for these differential changes
need to be examined in future studies in order to delineate the possible causes of these
observations. In addition, future studies will need to address the potential differences be-
tween serum and plasma levels of these lipid-derived mediators, given the distinctions noted
in our studies compared with findings of the other investigation [23].
There is accumulating evidence that the endocannabinoid system plays a key role
in increasing energy intake and enhancing energy preservation via several different
mechanisms, including inhibition of brown adipose tissue formation and thermogenesis [8,
11, 12]. For instance, it has been shown that reduced levels of 2-AG in the forebrain of mice
lead to increased brown adipose tissue thermogenesis and a lean body phenotype [30],
whereas CB1 receptor activation in white adipose tissue prevents the transdifferentiation
Table 3. Unadjusted and Adjusted Spearman Rank Correlation Coefficients (r) of Serum 2-AG
With Relevant Laboratory and Body Anthropometric Data in 96 Patients Undergoing Main-
tenance Hemodialysis
Variable
Unadjusted Adjusted
r P Value r P Value
Laboratory tests
Albumin, g/dL 0.05 0.62 0.08 0.47
Creatinine, mg/dL 0.02 0.86 0.03 0.83
Ferritin, ng/mL 0.03 0.78 0.07 0.56
TIBC, mg/dL 0.28 0.01 0.32 0.004
PTH, pg/mL 20.02 0.87 20.002 0.98
Lipid panel
VLDL-C, mg/dL 0.44 ,0.0001 0.42 ,0.0001
Triglycerides, mg/dL 0.47 ,0.0001 0.43 ,0.0001
Cholesterol, mg/dL 0.28 0.005 0.23 0.03
HDL-C, mg/dL 20.31 0.002 20.33 0.001
LDL-C, mg/dL 0.18 0.09 0.13 0.21
LPA-C, mg/dL 0.20 0.05 0.21 0.05
NHDL, mg/dL 0.37 0.0003 0.33 0.001
IL-6, pg/mL 20.05 0.65 0.009 0.94
Body mass index, kg/m2 0.43 ,0.0001 0.40 ,0.0001
Body anthropometry
Biceps skin fold, mm 0.34 0.0008 0.32 0.002
Triceps skin fold, mm 0.33 0.001 0.32 0.002
Midarm muscle circ, mm 0.09 0.40 0.12 0.29
Midarm circ, mm 0.34 0.0009 0.33 0.002
NIR body fat % 0.31 0.002 0.31 0.004
Adjusted model includes age, sex, race, ethnicity, diabetes, and dialysis vintage as covariates.
Abbreviations: circ, circumference; HDL-C, high-density lipoprotein cholesterol; IL-6, interleukin-6; LDL-C,
low-density lipoprotein cholesterol; LPA-C, lipoprotein(a) cholesterol; NHDL, non‒high-density lipoprotein;
NIR, near-infrared; PTH, parathyroid hormone; TIBC, total iron-binding capacity; VLDL-C, very-low-density
lipoprotein cholesterol.
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of white adipocytes into the thermogenic brown fat phenotype characterized by increased
UCP-1, resulting in an obese phenotype [31]. Furthermore, other clinical investigations
also found a positive correlation between circulating 2-AG levels and markers of body
mass, including body fat content [29]. Therefore, it is not surprising that increasing serum
levels of 2-AG positively correlate with indices of increased body mass in patients
undergoing hemodialysis.
Furthermore, activation of the endocannabinoid system via 2-AGmay also play a causative
role in elevated TG levels in ESRD. Dyslipidemia of CKD and ESRD is characterized by
increased levels of serum TGs and TG-rich lipoproteins [32]. One proposed mechanism
underlying these findings is activation of the nuclear transcription factor sterol regulatory
element binding protein-1c (SREBP-1c) in the liver and adipose tissue [33, 34]. In addition,
there is downregulation of the machinery involved in fatty acid b-oxidation, including car-
nitine palmitoyltransferase-1. Together, these alterations lead to increased TG production,
tissue content, and serum levels. It is interesting to note that activation of CB1 receptors (i.e.,
via increased 2-AG levels) has been also shown to stimulate SREBP-1c and decrease carnitine
palmitoyltransferase-1 activity and mRNA expression [35]. These effects have also been
shown to cause increased serum and hepatic TG content. Therefore, significantly increased
serum 2-AG levels, which may indicate overactivity of the endocannabinoid system, may also
be partly causing the hypertriglyceridemia observed in ESRD.
Several limitations of this study need to be mentioned. Although the findings described
here are thought-provoking, they remain observational in nature, and mechanistic studies
are needed to verify a causal link between serum2-AG levels and obesity/hypertriglyceridemia.
Similarly, the functional relationship between 2-AG and AEA, as well as the potential roles of
AEA and other fatty acid ethanolamides in ESRD, if any, remains to be determined. Fur-
thermore, although we adjusted for multiple variables, the possibility of residual confounding
cannot be excluded. Although 2-AG is a potent activator of the endocannabinoid system, the
role of circulating endocannabinoids in the activation of the endocannabinoid system has not
been fully elucidated. Another potential limitation is the use of nonfasting serum in the
analysis of lipid-derivedmediators. Althoughmany previous studies of serumendocannabinoid
levels used fasting serum or plasma samples [23], it should be noted that Gatta-Cherifi et al.
[36] showed that serum levels of 2-AG were not affected by feeding. In addition, we used
nonfasting serum across all of the groups in this study, including our healthy controls;
therefore, the likelihood of alterations in serum AEA and/or 2-AG levels due to timing of food
intake is less likely. Finally, our studies do not indicate the source of 2-AG in serum, and this
will need to be investigated in future studies. Potential mechanisms responsible for increased
serum 2-AG levels include increased production by the gastrointestinal tract [12], oxidative
stress‒related inhibition of monoacylglycerol lipase, the main enzyme responsible for 2-AG
breakdown, and activation of platelets and platelet activating factor in hemodialysis. This
latter mechanism can also potentially explain the differences in levels of 2-AG found in our
study, given that we used serum compared with Friedman et al. [23] who used plasma [37–39].
These pathways will need to be examined in future mechanistic studies to determine the
underlying cause of increased serum 2-AG in MHD patients.
In conclusion, serum concentrations of the endocannabinoidmediator 2-AGwere increased
in MHD patients and significantly and positively correlated with BMI, markers of increased
body mass, and serum TG concentrations. Future studies are needed to determine the
mechanisms responsible for these findings and the association of serum endocannabinoid
levels with ESRD-related outcomes.
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